Characterization of AZD4547: An orally bioavailable, potent and selective inhibitor of FGFR tyrosine kinases 1, 2 and 3

被引：2
|
作者：
Gayine, Paul R. [1 ]
Mooney, Lorraine [2 ]
Kilgour, Elaine [2 ]
Thomas, Andrew P. [2 ]
Al-Kadhimi, Katherine [2 ]
Beck, Sarah [2 ]
Coleman, Tanya [2 ]
Baker, Dawn [2 ]
Mellor, Martine J. [2 ]
Brooks, Nigel A. N. [2 ]
Klinowska, Teresa [2 ]
机构：
[1] AstraZeneca ICC, Shanghai, Peoples R China
[2] AstraZeneca R&D, Macclesfield, Cheshire, England
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-3568
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3568
引用
收藏
页数：1
相关论文
共 50 条
  • [1] AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
    Gavine, Paul R.
    Mooney, Lorraine
    Kilgour, Elaine
    Thomas, Andrew P.
    Al-Kadhimi, Katherine
    Beck, Sarah
    Rooney, Claire
    Coleman, Tanya
    Baker, Dawn
    Mellor, Martine J.
    Brooks, A. Nigel
    Klinowska, Teresa
    CANCER RESEARCH, 2012, 72 (08) : 2045 - 2056
  • [2] The discovery of AZD4547: An orally bioavailable, potent and selective N-(5-Pyrazolyl)benzamide FGFR1-3 inhibitor
    Thomas, Andrew P.
    Theoclitou, Maria-Elena
    Buttar, David
    Ruston, Linette
    Wrigley, Gail
    Dennis, Mike
    Rudge, David A.
    Coleman, Tanya
    Smith, Robin
    Gavine, Paul R.
    Klinowska, Teresa
    Mooney, Lorraine
    Brooks, Nigel
    CANCER RESEARCH, 2012, 72
  • [3] Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1
    Zuo-wei Wang
    Feng-ming Zou
    Ao-li Wang
    Jing Yang
    Rui Jin
    Bei-lei Wang
    Li-juan Shen
    Shuang Qi
    Juan Liu
    Jing Liu
    Wen-chao Wang
    Qing-song Liu
    Acta Pharmacologica Sinica, 2023, 44 : 801 - 810
  • [4] Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1
    Wang, Zuo-wei
    Zou, Feng-ming
    Wang, Ao-li
    Yang, Jing
    Jin, Rui
    Wang, Bei-lei
    Shen, Li-juan
    Qi, Shuang
    Liu, Juan
    Liu, Jing
    Wang, Wen-chao
    Liu, Qing-song
    ACTA PHARMACOLOGICA SINICA, 2023, 44 (04): : 801 - 810
  • [5] FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
    Xie, Liang
    Su, Xinying
    Zhang, Lin
    Yin, Xiaolu
    Tang, Lili
    Zhang, Xiuhua
    Xu, Yanping
    Gao, Zeren
    Liu, Kunji
    Zhou, Minhua
    Gao, Beirong
    Shen, Danping
    Zhang, Lianhai
    Ji, Jiafu
    Gavine, Paul R.
    Zhang, Jingchuan
    Kilgour, Elaine
    Zhang, Xiaolin
    Ji, Qunsheng
    CLINICAL CANCER RESEARCH, 2013, 19 (09) : 2572 - 2583
  • [6] Preclinical profile of AZD4547: A selective inhibitor of FGF-receptors 1, 2, and 3
    Brooks, Nigel A.
    CANCER RESEARCH, 2011, 71
  • [7] AZD4547, a potent FGFR inhibitor, regulates myelin gene expression in OLN-93 oligodendrocytes
    Sharifi, B.
    Rajendran, R.
    Berghoff, M.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 849 - 850
  • [8] AZD4547, a potent and selective inhibitor of FGF-receptor tyrosine kinases 1, 2 and 3, inhibits the growth of FGF-receptor 2 driven gastric cancer models in vitro and in vivo
    Xie, Liang
    Su, Xinying
    Zhang, David
    Tang, Lily
    Xu, Jessie
    Wang, Maggie
    Yin, Lucy
    Zhang, Jingchuan
    Ye, Katherine
    Wang, Zengquan
    Kilgour, Elaine
    Ji, Qunsheng
    CANCER RESEARCH, 2011, 71
  • [9] Mechanisms of Efficacy of the FGFR1–3 Inhibitor AZD4547 in Pediatric Solid Tumor Models
    Nikki Phanhthilath
    Sara Hakim
    Catherine Su
    Andrea Liu
    Divya Subramonian
    Jacqueline Lesperance
    Peter E. Zage
    Investigational New Drugs, 2020, 38 : 1677 - 1686
  • [10] Mechanisms of Efficacy of the FGFR1-3 Inhibitor AZD4547 in Pediatric Solid Tumor Models
    Phanhthilath, Nikki
    Hakim, Sara
    Su, Catherine
    Liu, Andrea
    Subramonian, Divya
    Lesperance, Jacqueline
    Zage, Peter E.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1677 - 1686
12345